CD112R Targeting Molecules for T-Cell Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for modulating T-cell responses are limited in effectively targeting and inhibiting the CD112R pathway, which plays a crucial role in immune regulation and tumor suppression, due to the complexity of T-cell cosignaling networks and the lack of specific ligands and receptors for therapeutic intervention.
Innovation Solution
The development of CD112R targeting molecules, including fusion polypeptides, complexes, and antibodies that specifically bind to CD112R, allowing for the modulation of T-cell responses by inhibiting CD112R activity, thereby enhancing or suppressing immune reactions in conditions like cancer and autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current immunotherapies are used to modulate T-cell responses, then T-cell activation can be influenced, but the ability to specifically target and inhibit the CD112R pathway is limited due to the complexity of T-cell cosignaling networks
Solution Approach 1:
The patent segments the complex T-cell cosignaling network by identifying and isolating the CD112R pathway as a distinct target. By focusing on the specific interaction between CD112R and its ligands (CD155, CD112), the invention divides the complex network into manageable components that can be selectively modulated, thereby achieving specific targeting without being overwhelmed by the overall system complexity.
Solution Approach 2:
The patent introduces CD112R as an intermediary target within the T-cell activation pathway. By developing therapies that specifically interact with CD112R (such as antibodies or fusion proteins), the invention creates a mediating mechanism that can selectively inhibit the pathway without requiring direct manipulation of the entire complex network, thus achieving precision targeting.
2Reliability
If the CD112R pathway is targeted for therapeutic intervention, then T-cell responses can be modulated, but the lack of specific ligands and receptors for therapeutic intervention limits effectiveness
Solution Approach 1:
The patent changes the therapeutic approach by shifting from using natural ligands to using engineered molecules. By modifying the molecular parameters of the therapy (such as using fusion proteins with specific binding domains or engineered antibodies), the invention creates therapeutics that can reliably interact with CD112R even though natural ligands are limited, thereby improving effectiveness.
Solution Approach 2:
The patent employs composite molecular structures, such as fusion proteins combining CD112R binding domains with functional domains (like Fc regions or cytokine domains). These composite molecules integrate multiple functions into a single therapeutic agent, enabling reliable T-cell response modulation while overcoming the limitations of natural ligand availability.
3Object-affected harmful factors
If CD112R activity is inhibited to enhance immune regulation, then tumor suppression may be achieved, but the complexity of the cosignaling network makes it difficult to predict and control outcomes
Solution Approach 1:
The patent applies an inverted approach by focusing on inhibition rather than activation. Instead of trying to activate the CD112R pathway to achieve tumor suppression, the invention inhibits the pathway (through blocking antibodies or fusion proteins) to achieve the desired immune regulation and tumor rejection. This inversion simplifies the approach by targeting a specific inhibitory mechanism within the complex network rather than attempting to activate multiple pathways simultaneously.
Data Source
AI summary
The present disclosure relates to compositions and methods for modulating T-cell mediated immune response in a subject in need thereof. The method includes administering to the subject an effective amount of a CD112R protein, a fusion polypeptide, a complex including CD112R and a second protein, or an anti-CD112R antibody of the present disclosure.